Nicotinamide Riboside

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

2023

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

Ingredient: Nicotinamide Riboside,Pterostilbene

Indication: Hepatic inflammation in NAFLD

Trial Type: Clinical Trial

Sponsor: Elysium

Journal: Hepatology

Authors: Rodney Butt